Search results
Results From The WOW.Com Content Network
Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines. . Released in beta in November 2004, the Google Scholar index includes peer-reviewed online academic journals and books, conference papers, theses and dissertations, preprints, abstracts, technical reports, and other ...
The Internet Archive Scholar is a scholarly search engine created by the Internet Archive in 2020. As of February 2024 [update] , it contained over 35 million research articles with full text access.
Cholinesterase inhibitors (ChEIs), also known as anti-cholinesterase, are chemicals that prevent the breakdown of the neurotransmitter acetylcholine or butyrylcholine by cholinesterase. This increases the amount of the acetylcholine or butyrylcholine in the synaptic cleft that can bind to muscarinic receptors , nicotinic receptors and others.
Alexandra Elbakyan at a conference at Harvard (2010). Sci-Hub was created by Alexandra Elbakyan, who was born in Kazakhstan in 1988. [22] Elbakyan earned her undergraduate degree at Kazakh National Technical University [23] studying information technology, then worked for a year for a computer security firm in Moscow, then joined a research team at the University of Freiburg in Germany in 2010 ...
The term 'inhibitor' is often used in a general sense to describe any compound used to prevent unwanted polymerisation, however these compounds are often divided into 'retarders' and 'true inhibitors'. A true inhibitor has a well defined induction period during which no noticeable polymerisation takes place. They are consumed during this period ...
Scholarpedia is an English-language wiki-based online encyclopedia with features commonly associated with open-access online academic journals, which aims to have quality content in science and medicine. Scholarpedia articles are written by invited or approved expert authors and are subject to peer review. [3]
An inhibitor can reduce the effectiveness of a catalyst in a catalysed reaction (either a non-biological catalyst or an enzyme).E.g., if a compound is so similar to (one of) the reactants that it can bind to the active site of a catalyst but does not undergo a catalytic reaction then that catalyst molecule cannot perform its job because the active site is occupied.
Defactinib (INN, codenamed VS-6063) is an inhibitor of PTK2, also known as focal adhesion kinase (FAK), Pyk2, and MELK which was developed by Pfizer and licensed to Verastem Oncology as a potential treatment for solid tumors. Development for mesothelioma was discontinued in 2015 due to lack of efficacy in a placebo-controlled phase II trial.